ConductScience.org, home

Comparison · NCT05094154-deaths

Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: deaths from any cause. Trial comparisons, record NCT05094154-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05094154-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.08570.07120.103wilson
Risk in group 20.08170.0680.0979wilson
Risk difference, group 1 minus group 20.00394-0.01780.0258newcombe hybrid score
Risk ratio, group 1 over group 21.050.8091.36log
Odds ratio, group 1 over group 21.050.7941.4log
Number needed to harm, for one more death from any cause on Anti-pseudomonal Cephalosporin than on Anti-pseudomonal Penicillin254from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Anti-pseudomonal Cephalosporin
Participants in the anti-pseudomonal cephalosporin arm will receive at least one dose of an anti-pseudomonal cephalosporin.~anti-pseudomonal cephalosporin: Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
1041,214EG000
Group 2Anti-pseudomonal Penicillin
Participants in the anti-pseudomonal penicillin arm will receive at least one dose of an anti-pseudomonal penicillin.~anti-pseudomonal penicillin: Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
1061,297EG001

Harm

What it counts
Total, all-cause mortality
Time frame
28 days.

Source ClinicalTrials.gov

Trial

Title
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
NCT number
NCT05094154
Phases
PHASE4
Conditions
Sepsis, AKI, Neurotoxicity
Interventions
anti-pseudomonal cephalosporin, anti-pseudomonal penicillin
Lead sponsor
Vanderbilt University Medical Center
Results first posted
2023-12-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05094154-deaths